Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib

References

• NCCNClinical Practice Guidelines in Oncology: Kidney Cancer2015 Version 1. Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdfAccessed August 28, 2017
   Google Scholar
• LjungbergBBensalahKCanfieldSEAU guidelines on renal cell carcinoma: 2014 updateEur Urol201567591392425616710
   PubMed Web of Science ®Google Scholar
• EscudierBPortaCSchmidingerMRenal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201425suppl 3iii49iii5625210086
   PubMed Web of Science ®Google Scholar
• AlimohamedNLeeJLSrinivasSA population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaClin Genitourin Cancer2014124e127e13124485801
   PubMedGoogle Scholar
• KoJJChoueiriTKRiniBIFirst-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCBr J Cancer201411081917192224691425
   PubMed Web of Science ®Google Scholar
• HengDYSignorovitchJSwallowEComparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studiesPLoS One2014912e11426425493562
   PubMed Web of Science ®Google Scholar
• BergmannLKubeUDoehnCEverolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional studyBMC Cancer20151530325925846
   PubMed Web of Science ®Google Scholar
• CalvoEEscudierBMotzerRJEverolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 studyEur J Cancer201248333333922209391
   PubMed Web of Science ®Google Scholar
• MotzerRJAlyasovaAYeDPhase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)Ann Oncol201627344144826681676
   PubMed Web of Science ®Google Scholar
• AlbigesLKubeUEymardJCEverolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studiesEur J Cancer201551162368237426276039
   PubMedGoogle Scholar
• KontovinisLLaschosKKaradimouASequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical studyMed Oncol201229275075421279702
   PubMedGoogle Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTECellaDPazopanib versus sunitinib in metastatic renal-cell carcinomaN Engl J Med2013369872273123964934
   PubMed Web of Science ®Google Scholar
• EscudierBPortaCBonoPRandomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES StudyJ Clin Oncol201432141412141824687826
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSRavaudARECORD-1 Study GroupEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• HengDYChoueiriTKRiniBIOutcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trialsAnn Oncol201425114915424356626
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJSchwartzLHPrognostic factors for survival in previously treated patients with metastatic renal cell carcinomaJ Clin Oncol200422345446314752067
   PubMed Web of Science ®Google Scholar
• ChoueiriTKEscudierBPowlesTMETEOR InvestigatorsCabozantinib versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191814182326406150
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFCheckMate 025 InvestigatorsNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTEGlenHLenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialLancet Oncol201516151473148226482279
   PubMed Web of Science ®Google Scholar
• VogelzangNJHackshawMDHutsonTEFirst-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor therapy among patients with advanced renal cell carcinoma in a US community oncology settingClin Genitourin Cancer201513321021725498215
   PubMed Web of Science ®Google Scholar
• BellmuntJPonsFForeshewASequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicityClin Genitourin Cancer201412426226924795159
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTEMcCannLDeenKChoueiriTKOverall survival in renal-cell carcinoma with pazopanib versus sunitinibN Engl J Med2014370181769177024785224
   PubMed Web of Science ®Google Scholar
• SoerensenAVDonskovFHermannGGImproved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2Eur J Cancer201450355356224215846
   PubMed Web of Science ®Google Scholar
• HengDYXieWReganMMPrognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyJ Clin Oncol200927345794579919826129
   PubMed Web of Science ®Google Scholar
• BamiasATzannisKPapatsorisAPrognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multi-institutional studyClin Genitourin Cancer201412537338324819319
   PubMedGoogle Scholar
• BamiasATzannisKBeuselinckBDevelopment and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaborationBr J Cancer2013109233234123807171
   PubMed Web of Science ®Google Scholar
• BamiasABonoPProcopioGPRINCIPAL: a prospective observational study of real-world treatment patterns and treatment outcomes in patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanibJ Clin Oncol2014325s sul;abstrTS4600^
   PubMedGoogle Scholar
• ChenCCHessGPLiuZSecond-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinomaClin Genitourin Cancer201210425626122682982
   PubMedGoogle Scholar
• BuchlerTBortlicekZPoprachAEfficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysisUrol Oncol201432556957524629497
   PubMed Web of Science ®Google Scholar
• GrunwaldVKarakiewiczPIBavbekSEREACT Study GroupAn international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyEur J Cancer201248332433221803569
   PubMed Web of Science ®Google Scholar
• EscudierBMichaelsonMDMotzerRJAxitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialBr J Cancer2014110122821282824823696
   PubMed Web of Science ®Google Scholar
• PowlesTStaehlerMLjungbergBUpdated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapyEur Urol20166914626508312
   PubMed Web of Science ®Google Scholar